**RESEARCH Open Access**

# Oxygen vacancy-engineered cerium oxide mediated by copper-platinum exhibit enhanced SOD/CAT-mimicking activities to regulate the microenvironment for osteoarthritis therapy

Junxu Yang<sup>1,3†</sup>, Shihui Xiao<sup>1,3†</sup>, Jiejia Deng<sup>1,2†</sup>, Yuquan Li<sup>1,5</sup>, Hao Hu<sup>1</sup>, Jiawei Wang<sup>1</sup>, Chun Lu<sup>4</sup>, Guanhua Li<sup>1,3</sup>, Li Zheng<sup>1\*</sup>, Qingjun Wei<sup>1,5\*</sup> and Jingping Zhong<sup>1\*</sup>

### **Abstract**

Cerium oxide (CeO<sub>2</sub>) nanospheres have limited enzymatic activity that hinders further application in catalytic therapy, but they have an"oxidation switch" to enhance their catalytic activity by increasing oxygen vacancies. In this study, according to the defect-engineering strategy, we developed PtCuO<sub>x</sub>/CeO<sub>2-X</sub> nanozymes as highly efficient SOD/ CAT mimics by introducing bimetallic copper (Cu) and platinum (Pt) into CeO<sub>2</sub> nanospheres to enhance the oxygen vacancies, in an attempt to combine near-infrared (NIR) irradiation to regulate microenvironment for osteoarthritis (OA) therapy. As expected, the Cu and Pt increased the  $Ce^{3+}/Ce^{4+}$  ratio of  $CeO<sub>2</sub>$  to significantly enhance the oxygen vacancies, and simultaneously  $CeO<sub>2</sub>$  (111) facilitated the uniform dispersion of Cu and Pt. The strong metalcarrier interaction synergy endowed the PtCuO<sub>x</sub>/CeO<sub>2-X</sub> nanozymes with highly efficient SOD/CAT-like activity by the decreased formation energy of oxygen vacancy, promoted electron transfer, the increased adsorption energy of intermediates, and the decreased reaction activation energy. Besides, the nanozymes have excellent photothermal conversion efficiency (55.41%). Further, the PtCuO<sub>x</sub>/CeO<sub>2-X</sub> antioxidant system effectively scavenged intracellular ROS and RNS, protected mitochondrial function, and inhibited the infammatory factors, thus reducing chondrocyte apoptosis. In vivo, experiments demonstrated the biosafety of PtCuO<sub>X</sub>/CeO<sub>2-X</sub> and its potent effect on OA suppression. In particular, NIR radiation further enhanced the effects. Mechanistically, PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanozymes reduced ras-related C3 botulinum toxin substrate 1 (Rac-1) and *p*-p65 protein expression, as well as ROS levels to remodel the infammatory microenvironment by inhibiting the ROS/Rac-1/nuclear factor kappa-B (NF-κB) signaling pathway. This study introduces new clinical concepts and perspectives that can be applied to infammatory diseases.

**Keywords** Nanozymes, Oxygen vacancies, Enzyme catalytic activity, Anti-infammatory, Osteoarthritis

† Junxu Yang, Shihui Xiao and Jiejia Deng have contributed equally to this work.

\*Correspondence: Li Zheng zhengli224@163.com Qingjun Wei weiqingjungxnn@163.com Jingping Zhong jingpingzhong@163.com Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modifed the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit<http://creativecommons.org/licenses/by-nc-nd/4.0/>.



#### **Introduction**

Osteoarthritis (OA) is a destructive infammatory articular cartilage disease afecting 528 million people worldwide  $[1]$  $[1]$ . Currently, there are no effective therapeutic drugs for OA, and joint replacement surgery can only be performed in the late stages of the disease, which causes tremendous pain to patients  $[2, 3]$  $[2, 3]$  $[2, 3]$  $[2, 3]$ . Therefore, there is an urgent need to develop new treatment strategies for OA. According to research, excessive reactive oxygen species (ROS) and reactive nitrogen species (RNS) and their activated nuclear factor kappa-B (NF-κB) signaling pathway, leading to oxidative stress, were closely related to the pathogenesis of OA  $[4-6]$  $[4-6]$  $[4-6]$ . Therefore, an effective means of treating OA involves scavenging the overproduced ROS and RNS, such as superoxide anion  $(O_2^-)$ , hydroxyl radical ( $\cdot$ OH), hydrogen peroxide ( $H_2O_2$ ), and nitric oxide (·NO[\)7](#page-19-10). Natural catalase (CAT) and superoxide dismutase (SOD) are the antioxidant defense systems in the body, but in the OA, excessive ROS and RNS disrupt the balance of the redox system [[8\]](#page-19-11). Direct supplementation of natural SOD and CAT has limitations, including complex synthesis and purifcation processes [\[9](#page-19-12)], poor thermal stability  $[10]$  $[10]$ , and short shelf life  $[11]$  $[11]$  $[11]$ . Therefore, researchers aim to design efficient artificial enzymes that mimic the catalytic activity of natural enzymes.

Nanozymes offer significant advantages, such as high enzyme-like activity [\[12\]](#page-19-15), good stability [[13](#page-19-16)], low cost [[14\]](#page-19-17), and controllable synthesis, which have attracted wide attention and recognition. Among them, cerium oxide ( $CeO<sub>2</sub>$ ) was well known to exhibit various enzymemimetic properties for the treatment of infammatory diseases, such as SOD and CAT, which was achieved by modulating the electronic structure through reversible  $Ce^{3+}$  (reduction) and  $Ce^{4+}$  (oxidation) transitions [[15\]](#page-19-18). For example, Gao et al.  $[16]$  $[16]$  used hyaluronic acid/ serotonin-modified  $CeO<sub>2</sub>$  nanomedicine to mimic SOD/

CAT-like activities for scavenging ROS, thereby removing infammatory factors and facilitating intestinal epithelial barrier repair for ulcerative colitis therapy. Lin et al. [[17](#page-19-0)] used hyaluronic acid-loaded  $CeO<sub>2</sub>$  as a ROS scavenger that protected chondrocytes from IL-1β-induced oxidative stress damage for OA therapy. Although  $CeO<sub>2</sub>$ -based nanozymes show promising therapeutic potential for infammatory diseases, they still face challenges, including low enzyme activity, high toxicity, and easy aggregation [[18](#page-19-1)[–20](#page-19-2)].

Excitingly, the doping of copper (Cu) nanospheres on CeO<sub>2</sub> can improve the ratio of the Ce<sup>3+</sup>/Ce<sup>4+</sup> in CeO<sub>2</sub> to signifcantly increase the occupancy of oxygen vacancies and expose more active sites, thus further enhancing its catalytic activity. For example, Guo et al. [\[21\]](#page-19-3) demonstrated that doping Cu in  $CeO<sub>2</sub>$  weakened the Ce–O bonds, which facilitated the generation of oxygen vacancy active sites, and the synergistic interactions enhanced the catalytic activity for  $CO<sub>2</sub>$  reduction. In addition, Zhang et al. [\[22\]](#page-19-4) demonstrated that  $Cu/CeO<sub>2</sub>$  had higher adsorption energy for reactants than noble metals (such as Pd and Au), making it more favorable for  $H_2$  dissociation reactions. However, the development of Cu-loaded CeO<sub>2</sub> nanospheres to mimic the activities of natural SOD/CAT enzymes has rarely been reported, possibly because  $Cu^{1+}$ has more catalytic activity than  $Cu^{2+}$ , but  $Cu^{1+}$  is unstable, resulting in insufficient catalytic activity and stability [[23\]](#page-20-0). Fortunately, introducing platinum (Pt) into Cu can stabilize the  $Cu^{1+}$ , synergistically enhancing CO oxidation [[24\]](#page-20-1). And Zou et al. [[25\]](#page-20-2) demonstrated that the addition of Pt changed the charge state of the Cu surface, and Cu also modulated the d-band center of Pt, thus optimizing the catalytic performance of  $CO<sub>2</sub>$  reduction. In addition, photothermal therapy has been shown to enhance the enzymatic activity of nanozymes, thereby improving the therapeutic effect  $[26]$  $[26]$ . Therefore, we expected that Cu/Pt co-loaded  $CeO<sub>2</sub>$  could enhance the photothermal efect under near-infrared (NIR) irradiation and further optimize the catalytic activity of SOD/CAT-like enzymes, thus providing a synergistic therapy for OA, which has not been reported in the literature.

Here, a "defect engineering construction strategy" [[27](#page-20-4)] was employed to develop  $PtCuO<sub>x</sub>/CeO<sub>2-x</sub>$  nanozymes as highly efficient SOD/CAT mimics by introducing bimetallic Cu and Pt into  $CeO<sub>2</sub>$  microspheres to enhance the oxygen vacancies, in an attempt to combine NIR irradiation to regulate microenvironment for OA therapy. As expected, the Cu and Pt increased the  $Ce^{3+}/Ce^{4+}$ ratio of  $CeO<sub>2</sub>$  to significantly enhance the oxygen vacancies, and simultaneously  $CeO<sub>2</sub>$  (111) facilitated the uniform dispersion of Cu and Pt. The strong metal-carrier interaction synergy endowed the PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanozymes with highly efficient SOD/CAT-like activity by the decreased formation energy of oxygen vacancy,

promoted electron transfer, the increased adsorption energy of intermediates, and the decreased reaction activation energy. Besides, the nanozymes have excellent photothermal conversion efficiency (55.41%). In vitro experiments demonstrated that the PtCuO<sub>X</sub>/CeO<sub>2-X</sub> SOD/CAT antioxidant system efectively eliminated ROS and RNS, restored mitochondrial function, and inhibited the infammatory factors, leading to a reduction in chondrocyte apoptosis. In vivo experiments demonstrated the biosafety of PtCuO<sub>X</sub>/CeO<sub>2-X</sub> and the potent effect on OA progression. In particular, NIR radiation further enhanced the effects. Mechanistically,  $PtCuO<sub>x</sub>/CeO<sub>2-X</sub>$ nanozymes reduced ras-related C3 botulinum toxin substrate 1(Rac-1) and *p*-p65 protein expression, as well as ROS levels to remodel the infammatory microenvironment by inhibiting the ROS/Rac-1/NF-κB signaling pathway (Fig. [1](#page-2-0)).



<span id="page-2-0"></span>Fig. 1 PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanozymes scavenge ROS in chondrocytes, improve mitochondrial function, and treat OA. CuPt-loaded nanospheres loaded increased the Ce<sup>3+</sup>/Ce<sup>4+</sup> ratio, accelerated the electron transfer, sufficiently exposed the active sites, increased the oxygen vacancy content and the free radicals adsorption energy, and lowered the activation energy barriers to enhance SOD/CAT-like activity. PtCuO<sub>x</sub>/CeO<sub>2-X</sub> nanozymes remodel the infammatory microenvironment by inhibiting the ROS/Rac-1/NF-κB pathway

#### **Materials and methods**

#### **Methods for synthesis and characterization of nanozymes** *Materials*

Cerium nitrate hexahydrate  $(CeN_3O_9.6H_2O, 99.5\%)$ was purchased from Macklin Company in China. Hydrazine hydrate  $(N_2H_4·H_2O, AR)$  and copper sulfate ( $CuSO<sub>4</sub>·5H<sub>2</sub>O$ , AR) were purchased from Chengdu Jinshan Chemical Reagent Co. Anhydrous ethanol was purchased from China National Pharmaceutical Chemical Reagent Co. Platinum tetrachloride  $(PLC)_{4}$  and ethylene glycol  $(C_2H_4O_2, > 99%)$  were purchased from Macklin Company in China. All chemicals were used directly without further purifcation.

#### Synthesis of CeO<sub>2</sub>

The nanoparticles were synthesized based on previ-ous research [\[28–](#page-20-5)[30\]](#page-20-6). Ce(NO<sub>3</sub>)<sub>3</sub>·6H<sub>2</sub>O (4.6 mmol/L) was dissolved in 2 mL of deionized water, followed by the addition of acetic acid (2 mL) and ethylene glycol  $(52 \text{ mL})$ . The solution was transferred to a Teflon liner, maintained at 180 °C for 200 min, centrifuged and dried to obtain the product, and calcined in air at 400 °C for 4 h to obtain  $CeO<sub>2</sub>$  nanospheres.

#### *Synthesis of PtCuO*<sub> $X$ </sub>/CeO<sub>2-X</sub>

 $CuSO<sub>4</sub>$  (50 mg) and  $CeO<sub>2</sub>$  (100 mg) were dissolved in deionized water (4 mL), respectively, added to 80 mL of anhydrous ethanol, and hydrazine hydrate was added dropwise and reacted for 2 h to give the intermediate product,  $CuO<sub>x</sub>/CeO<sub>2-x</sub>$ . Similarly, PtCl<sub>4</sub> (20 mg) and  $CuO<sub>X</sub>/CeO<sub>2-X</sub>$  (100 mg) were dissolved in deionized water (4 mL) in the same manner as above. PtCuO<sub>X</sub>/  $CeO<sub>2-X</sub>$  nanospheres were obtained.

#### *Characterization methods*

Transmission electron microscopy (TEM) and energy dispersive spectroscopy (EDS) (FEI Talos f200s, FEI, USA) were used to determine the morphology, size, and composition of the nanospheres. Dynamic light scattering (DLS) (Zetasizer Nano ZS ZEN3600, Malvern, UK) was used for hydrodynamic diameters of nanospheres, and X-ray photoelectron spectroscopy (XPS) (Thermo Fisher ESCALAB 250Xi, USA) was used for structure–activity relationships of nanospheres. An X-ray difractometer (Rigaku, Ultima IV, Japan) was used for the crystallinity of nanospheres. An inductively coupled plasma mass spectrometer (Thermo iCAP 6300 Duo, USA) was used for the determination of elemental content, and the JEOL JES FA200 ESR spectrometer was used for the evaluation of free radical scavenging capacity. Fourier transform infrared spectrometer (IRAfnity-1S, Shimadzu, Japan) was used for infrared absorption.

#### **DFT computational details**

All DFT calculations were carried out using the Vienna ab initio simulation package (VASP)  $[31]$  $[31]$  $[31]$ . The Perdew-Burke-Ernzerhof (PBE) [[32\]](#page-20-8) functional was used to treat the exchange–correlation interactions. The plane wave basis set with a kinetic energy cutoff of 400 eV and the energy convergence criterion of  $10^{-4}$  eV was used for structure relaxation. All surface calculations used a  $(1 \times 1 \times 1)$  Monkhorst–Pack k-point sampling.  $H_2O$ ,  $H_2O_2$  and  $O_2$  were calculated in boxes of  $15\text{\AA} \times 15\text{\AA} \times 15\text{\AA}$ , with the gamma point only.

The adsorption energy  $(E_{ads})$  is calculated as follows:

$$
E_{ads} = \; E_{(adsorbates \; + \; catalysts)} \; - \; E_{adsorbates} \; - \; E_{catalysts}
$$

 $E_{(adsorbates + catalysts)}$ ,  $E_{adsorbates}$ , and  $E_{catalvsts}$  are the energy of the whole system, adsorbates, and catalysts, respectively.

#### **Photothermal performance testing** *Photothermal heating curve*

 $\text{CeO}_2$  and  $\text{PtCuO}_X/\text{CeO}_{2\text{-}X}$  solutions (1 mL, 50  $\mu\text{g/mL})$ were placed in Eppendorf tubes, respectively. The samples were irradiated with an 808 nm laser (RAL808T1, Quartz Laser, China) for 15 min. Temperature changes were recorded and thermographic photographs were taken.

#### *Photothermal conversion efficiency of PtCuO<sub>X</sub>/CeO<sub>2</sub></del>*

PtCuO<sub>X</sub>/CeO<sub>2-X</sub> solution (1 mL, 50 µg/mL) was irradiated with an 808 nm laser for 900 s. The laser was then turned off and allowed to cool naturally. The photothermal conversion efficiency (η) of the PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanospheres was then calculated using Eqs.  $(1)-(4)$  $(1)-(4)$  $(1)-(4)$  $(1)-(4)$  $(1)-(4)$ .

<span id="page-3-0"></span>
$$
\Delta T_{\text{max}} = T_{\text{max}} - T_{\text{surr}} \tag{1}
$$

<span id="page-3-1"></span>
$$
\eta = (h A * \Delta T_{\text{max}} - Qs) / (I * (1 - 10 - A\lambda)) \tag{2}
$$

$$
\tau s = M_D * C_D / h A \tag{3}
$$

$$
\theta = (\Delta T) / (\Delta T_{\text{max}}) \tag{4}
$$

(where " $\eta$ " is the photothermal conversion coefficient, "h" is the heat transfer coefficient, "A" is the surface area of the vessel, and "h A" can be determined by a linear relationship between time and the negative logarithm of the cooling cycle (-lnθ). " $T_{max}$ " is the equilibrium temperature, " $T_{\text{surr}}$ " is the ambient temperature, "Qs" is the

heat generation of the solvent, "I" is the irradiated laser power, "A $\lambda$ " is the absorbance of the PtCuO<sub>x</sub>/CeO<sub>2-X</sub> nanospheres at 808 nm, "τs" is the time, " $M_D$ " is the mass of the solvent, " $C_D$ " is the heat capacity of the solvent, "θ" is the cooling cycle, and " $\Delta T$ " is the temperature difference during a given period).

The calculation procedure is as follows:  $\Delta T_{\text{max}} = T_{\text{max}} - T_{\text{surr}} = 48.1 - 25 = 23.1$ °C hA =  $M_D$  \*  $C_D$  / τs = 4.2\*1/335.2 = 0.01252.<br>Qs =  $M_D$  \*  $C_D$  (T<sub>PRS</sub>-T<sub>surr</sub>) = 4.2  $(T_{\text{PBS}}-T_{\text{surr}})=4.2*0.001*(28.2–$  $25) = 0.0013$ .  $\eta = (hA \triangle T_{max} - Qs)$  /(I(1–10- A))) = (0.0125\*23.1–

0.0013)  $/\pi$ \*0.52\*(1-10-0.47) = 0.5541.

#### *Photothermal stability*

PtCuO<sub>X</sub>/CeO<sub>2-X</sub> was dissolved in PBS (50  $\mu$ g/mL) and irradiated with NIR light for 15 min before stopping the irradiation and allowing it to cool to room temperature before starting the next round of irradiation. This was repeated four times and the temperature changes were recorded to evaluate the photothermal stability.

#### **Stability experiments of nanospheres**

The dispersion of  $PtCuO<sub>x</sub>/CeO<sub>2-x</sub>$  was recorded over 7 days and in diferent solvents. In addition, the average particle size and the polydispersity index (PDI) of the nanospheres in diferent solvents were measured by dynamic light scattering.

## **Enzyme mimetic properties of nanospheres**

### *H***2***O***2** *decomposition test*

We investigated the decomposition of  $H_2O_2$  by PtCuO<sub>X</sub>/  $CeO<sub>2-X</sub>$ . Briefly, H<sub>2</sub>O<sub>2</sub> solution (5 µL, 10 mM) was added to PtCuO<sub>X</sub>/CeO<sub>2-X</sub> aqueous solution (5 mL, 50  $\mu$ g/ mL). The amount of oxygen released was quantified using a portable dissolved oxygen meter. The ability of the PtCuO<sub>x</sub>/CeO<sub>2-X</sub> to continuously decompose H<sub>2</sub>O<sub>2</sub> in vitro and in vivo was evaluated by adding  $H_2O_2$  solution at the same time intervals using water and synovial fuid from OA rats, respectively, as the reaction system and the amount of oxygen released was recorded for four consecutive times.

#### *ESR for ·OH detection*

A solution of  $H_2O_2$  derived from hydroxyl radicals was generated by full-band xenon irradiation for 5 min and scavenged with 5-tert-butylcarbonyl-5-methyl-1-pyrroline-N-oxide (BMPO, 10 mM). The scavenging ability of PtCuO<sub>X</sub>/CeO<sub>2-X</sub> towards ·OH was evaluated by monitoring the changes in peak intensities compared to the control.

#### *ESR for ·O***<sup>2</sup> <sup>−</sup>** *detection*

In the ESR experiments, the  $\cdot O_2$ <sup>-</sup> was generated from  $KO<sub>2</sub>$  using 18-crown-6 as a stabilizer, while 5-(deoxy)-5-tert-butylcarbonyl-5-methyl-1-pyrroline-N-oxide (DMPO) was used as a scavenger. Peak intensities were measured for PtCuO $_X/CeO_{2-X}$  nanozymes and control materials.

#### *·O***<sup>2</sup> <sup>−</sup>***, H***2***O***2***, ·OH, and DPPH scavenging ability*

The ability of  $CeO_2$ , PtCuO<sub>X</sub>/CeO<sub>2-X</sub>, and PtCuO<sub>X</sub>/CeO<sub>2-</sub>  $_X +$ NIR to scavenge  $·O_2$ <sup>-</sup> was compared using a total superoxide dismutase assay kit (Beyotime, China). In addition, to verify whether the SOD-like activity of the nanozymes was concentration-dependent, the removal of  $\cdot{\rm O_2}^-$  by PtCuO<sub>X</sub>/CeO<sub>2-X</sub> at concentrations of 20, 50, and 100 mg/mL was compared. The absorbance at 450 nm was measured using an enzyme-labeling device (Thermo Scientifc, USA), and then the free radical scavenging rate was determined.

The scavenging activities of CeO<sub>2</sub>, PtCuO<sub>X</sub>/CeO<sub>2-X</sub>, and PtCuO<sub>X</sub>/CeO<sub>2-X</sub> + NIR against H<sub>2</sub>O<sub>2</sub>, ·OH, DPPH, and total ROS were compared using the catalase assay kit (Beyotime, China), the hydroxyl radical scavenging capacity assay kit (Solarbio, China), the DPPH radical scavenging capacity assay kit (Solarbio, China), and the total antioxidant capacity assay kit (Beyotime, China), respectively.

#### **Primary chondrocyte harvest and culture**

Sprague–Dawley (SD) rats were obtained from the Experimental Animal Center of Guangxi Medical University, and their articular cartilage was harvested and primary chondrocytes were extracted. The fresh cartilage tissue was minced, digested with trypsin for 30 min, centrifuged, resuspended with type II collagenase, and further digested for 4 h. Finally, cells were cultured in DMEM medium. Subsequent validation using third-generation anterior chondrocytes.

#### *Cellular uptake assay*

*Grafting of fluorescent groups to nanospheres*  $PtCuO<sub>X</sub>/$  $CeO<sub>2-X</sub>$  nanospheres (0.5 g) were added to a mixture of 3-aminopropyltrimethoxysilane (120 μL) and 95% ethanol (6 mL) and reacted for 1 h under light protection to obtain the intermediate containing amino-functionalized nanospheres. Dissolve 0.1 g of the above product in dimethylsulfoxide (400 μL), add Cy5-NHS ester (60 μL), then add dimethylsulfoxide until the volume reaches 800 μL, add 20 μL of triethylamine, and react for 24 h away from light.

*Cellular uptake* The chondrocytes  $(0.5 \times 10^5 \text{ cells/well})$ were inoculated into 6-well plates, and after 24 h of culture, Cy5-PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanospheres (50 μg/mL) were

#### *Cell viability assay*

Chondrocytes were cultured to attachment, co-cultured with the addition of nanospheres (30, 40, 50, 60, 70, and 80 μg/mL), and the cytotoxicity of nanozymes was evaluated by measuring the absorbance at 450 nm using a cell counting kit-8 (CCK-8, Biosharp, China) and a microplate reader (Molecular Devices, USA). In addition, the protective efect of nanozymes on infammatory chondrocytes was evaluated. Briefy, chondrocytes were cultured to attachment, IL-1β was added, the culture was continued for 12 h, 50  $\mu$ g/ml of nanozymes was added, and cell viability was determined after 24 h using a CCK-8 kit.

#### *Observation of live and dead cell staining*

Chondrocytes were cultured to adherence induced by the addition of IL-1β (10  $\text{ng/mL}$ ) for 12 h and then cocultured with the addition of CeO<sub>2</sub>, PtCuO<sub>x</sub>/CeO<sub>2-X</sub>, or PtCuO<sub>X</sub>/CeO<sub>2-X</sub> + NIR (1.0 W/cm<sup>2</sup>, 5 min) for 24 h. Cells were incubated with 1 μM calcein-AM and 1 μM propidium iodide (PI) for 30 min. Dead and live cells were then observed and recorded under a fuorescence microscope.

#### **Measurement of ROS scavenging capacity in vitro** *DCFH‑DA Probe*

ROS scavenging ability was detected using the fuorescent probe DCFH-DA (Beyotime, China). Chondrocytes  $(1 \times 10^5 \text{ cells/well})$  were cultured until wall-adherent and induced by IL-1 $\beta$  for 12 h, then CeO<sub>2</sub>, PtCuO<sub>X</sub>/CeO<sub>2-X.</sub> and PtCuO<sub>X</sub>/CeO<sub>2-X</sub> + NIR were added and cultured for 24 h, the probes were added, and the images were captured by fuorescence microscope (BD Biosciences, USA) after 30 min.

#### *DAF‑FM DA Probe*

Nitric oxide (NO) levels in chondrocytes were detected using the Nitric Oxide Fluorescent Probe Assay Kit (Beyotime, China). Cells were treated in the same way as the image acquisition process described above.

#### *DHE Probe*

The level of intracellular superoxide  $(\cdot O_2^-)$  was detected with the fluorescent probe DHE (Beyotime, China). The chondrocytes were treated as described above. Fluorescence images of each group of chondrocytes after diferent treatments were captured by fuorescence microscope.

#### *HPF probe*

The intracellular hydroxyl radicals (·OH) levels were detected using the HPF fuorescent probe. Cells were treated in the same way as the image acquisition process described above.

#### *[Ru (DPP)3]CI2 (luminescent oxygen sensor)*

The chondrocytes were treated as described above. Each group received an addition of [Ru(DPP)3]Cl2 (0.01 mg/ mL, 10 μL), and fuorescence imaging was performed by fuorescence microscopy.

#### **qRT‑PCR**

Chondrocytes  $(1 \times 10^5 \text{ cells/well})$  were cultured to adherence, induced with IL- $β$  for 12 h, and then co-cultured with  $CeO_2$ , PtCuO<sub>X</sub>/CeO<sub>2-X</sub>, and PtCuO<sub>X</sub>/CeO<sub>2-X</sub> + NIR for 24 h. Total RNA was extracted with TRIZOL and cell lysis bufer, and cDNA was reverse transcribed with PrimeScript according to the instructions. qRT-PCR was performed by adding SYBR premix to the cDNA of the real-time PCR system (Thermo Fisher, USA), preincubating for 1 cycle at 95 °C for 600 s, followed by 45 cycles at 95 °C for 10 s, and amplifying at 60 °C for 60 s. The  $2^{-\Delta\Delta Ct}$ method was used to quantify relative mRNA expression, normalized to GAPDH. The experiment was repeated in triplicate. Primer sequences are shown in Table [1](#page-5-0).

#### <span id="page-5-1"></span>**Immunofuorescence of relevant infammatory genes, chondroprotective genes, and apoptosis‑related factors**

Chondrocytes  $(1 \times 10^5 \text{ cells/well})$  were cultured until apposition, induced by the addition of IL-1β for 12 h, and then co-cultured with the addition of CeO<sub>2</sub>, PtCuO<sub>X</sub>/  $CeO<sub>2-X</sub>$ , and PtCuO<sub>X</sub>/CeO<sub>2-X</sub> + NIR for 24 h. Cells were fxed with 4% paraformaldehyde solution (Biosharp, China) for 15 min, permeabilized with 3%  $H_2O_2$  for 30 min, and blocked with goat serum for 30 min to

<span id="page-5-0"></span>



detect non-specific antibodies. IL-6 (Affinity Biosciences, #DF6087), MMP-13(Proteintech Group,#18,165– 1-AP), Col2a1(Afnity Biosciences,#AF0135), Bcl-2(Affinity Biosciences,#AF6139), Bax(Affinity Biosciences,#AF0120), Caspase-3(Affinity Biosciences,#AF6311) and β-actin(Afnity Biosciences,#AF7018) antibodies were incubated for 8–12 h, followed by FITC-conjugated anti-rabbit IgG (Boston, China) for 1 h. Finally, fuorescence images were captured with a fuorescence microscope (Olympus, Japan) and quantified using ImageJ software.

#### **Mitochondrial membrane potential assay** *JC‑1 fuorescent staining*

Cells were treated as described above, and after cells were incubated with JC-1 (Solarbio, China) working solution for 20 min, changes in JC-1 monomers and aggregates were recorded under a fuorescence microscope for each group, and fuorescence intensities were quantifed using ImageJ software.

#### *JC‑1 fow cytometry*

Cells were treated as described above. Cells in each treatment group were stained with a JC-1 fuorescent probe for 30 min, and the cells were washed three times with 4 °C PBS to precipitate. The intensity of red and green fluorescence signals were detected by flow cytometry (BD FACSCaliburTM Flow Cytometer).

#### **Cytoplasmic Ca<sup>2</sup><sup>+</sup> concentration assay**

Cell culture and treatment as described in Sect. "[Immu](#page-5-1)[nofuorescence of relevant infammatory genes, chondro](#page-5-1)[protective genes, and apoptosis-related factors"](#page-5-1), and at the end of the treatment, Fluo-4 AM (Beyotime, China) solution was co-incubated with chondrocytes for 30 min, and the fuorescence intensity of the cells was observed by fuorescence microscopy and fnally quantitatively analyzed by fuorescence using ImageJ.

#### **ATP measurement**

Cell culture was performed as described above, and after 24 h, the cells were treated with IL-1β for 12 h. According to the Enhanced ATP Assay Kit (Beyotime, China) instructions, the cells of each group were completely lysed, and the standard curve was plotted frst, after which the ATP content of each group was analyzed and calculated using a fuorescence microplate reader.

#### **Apoptosis detection**

Chondrocytes were cultured until apposition, then induced with IL-1 $\beta$  for 12 h. CeO<sub>2</sub>, PtCuO<sub>X</sub>/CeO<sub>2-X</sub>, and PtCuO<sub>x</sub>/CeO<sub>2-X</sub> + NIR were added to co-cultivate the

cells for 24 h. Cells were then counted and  $1.0 \times 10^5$  cells were collected, apoptosis detection reagents were added, and the cells were mixed and incubated away from light for 15 min, and the ratio of apoptosis was detected using Annexin V-APC /7-AAD Apoptosis Detection Kit (Key-GEN BioTECH, China) and flow cytometry (FCM) and analyzed by FlowJo\_V10 software.

#### **Immunoblotting assay for apoptosis‑related proteins and ROS/Rac‑1/NF‑κB pathway proteins**

The expression of apoptotic proteins and inflammatory pathway-related proteins was detected by Western blotting analysis using the following protein species and antibody sources: Caspase-3(Afnity Biosciences,#AF6311), Bcl-2(Afnity Biosciences,#AF6139), Bax(Affinity Biosciences,#AF0120), Rac-<br>1(Affinity Biosciences,#AF4200), p65(Affinity Biosciences,#AF4200), Biosciences,#AF5006), *p*-p65(Affinity Biosciences,#AF2006). The cell treatment was the same as above, and then the proteins were extracted, gel electrophoresis was performed, the membrane was transferred, the membrane was closed, the primary antibody was incubated for 8 h, and the secondary antibody was incubated for 1 h, and the protein bands were observed by BIO-RAD imaging system, and the intensity of the bands was analyzed by ImageJ software.

#### **Establishment of a rat OA model**

With the ethical approval of the Ethics Committee of Guangxi Medical University, the OA model was established using the anterior cruciate ligament transection (ACLT) method in randomized groups of 60 rats, body weight: 200–220 g, male SD rats, and rearing temperature: 23–25 °C. Treatments: weekly injection of drugs and NIR irradiation in the light group twice a week for 5 min each. Samples were collected in batches after 4 and 8 weeks of continuous treatment.

#### **IVIS imaging evaluation**

The Cy5-labeled PtCuO<sub>X</sub>/CeO<sub>2-X</sub> and the free Cy5 were injected into a knee joint of the rat. Then the IVIS images were collected by IVIS Spectrum Imaging System (BLT, China) at predetermined times (excitation wavelength 675 nm, emission wavelength 680 nm). In addition, the important organs were also scanned by the IVIS system to clarify the metabolic pathway of PtCu $O_X/CeO_{2-x}$ .

#### **Thermographic analysis of rat knee joints**

The right knee joints of rats were injected with PBS, CeO<sub>2</sub>, and PtCuO<sub>X</sub>/CeO<sub>2-X</sub> (100 μL, 50 μg/mL), respectively. 12 h later, the right knee joints were irradiated with NIR light. Images and temperatures during NIR irradiation were recorded with an anterior NIR camera.

#### **Gait analysis**

After successful modeling of OA, the gait of rats at weeks 4 and 8 was analyzed using the Animal Visual Gait Analysis System. Gait duration and mean gait speed were assessed.

#### **Histologic analysis**

#### *Enzyme‑linked immunosorbent assay (ELISA)*

We used IL-6(MEIMIAN, #MM-0190R2), MMP-13(MEIMIAN, #MM-0110R2), and Col2a1(Zeye Bio, #ZY0324ER) ELISA kits to detect the expression of related proteins in joint fuid and cell supernatants of OA rats, and IL-1β (Solarbio, #SEKR-0002), IL-17 (Solarbio, #SEKR-0007), and TGF-α (Zeye Bio, #ZY0126ER) kits to detect the expression of immune response-related factors. Add specimens according to instructions, incubate at 37 °C for 30 min, and wash 5 times with Wash Solution. Add 50 μL enzyme reagent, incubate for 30 min, wash 5 times, add dyes A and B sequentially, incubate for 10 min at 37 °C without light and add the termination solution. Measure the absorbance (OD value) of each well using an enzyme meter. Calculate the concentration from the standard curve.

#### *Immunohistochemistry staining (IHC)*

Tissue sections were routinely deparaffinized and dehydrated using a universal two-step detection kit (ZSGB-BIO, China, #PV-9000), and the antibody was diluted 1:200 and incubated overnight at 4 °C, protected from light, and then conjugated with biotinylated secondary antibody. The slides were photographed with a light microscope (OLYMPUS BX53F, Japan).

#### *Hematoxylin–eosin (HE) and safron‑o‑fast green staining*

Tissue sections and major organs were stained with hematoxylin–eosin kit (HE, Solarbio, China), safron-ofast green staining kit (Solarbio, China), and the sections were observed under a microscope and photographed for histological analysis. In addition, Venous blood samples were collected for routine and blood biochemical analyses to evaluate the biotoxicity of the nanozymes.

#### **Tissue reactive oxygen species assay**

Tissue homogenate was prepared by adding 1 mL bufer to 50 mg of knee cartilage tissue, 190 μL supernatant was collected by centrifugation, 10 μL BBcellProbeTM O11 ROS probe (BestBio, China) was added, and the tissue was incubated at 37 °C for 30 min under light protection. The ROS level was determined using a fluorescence

microplate reader (Bio-Tek Instruments, USA) with an excitation wavelength of 488 nm and an emission wavelength of 530 nm.

#### **Nanozymes cartilage penetration capability test**

100 μL of Cy5-PtCuO<sub>X</sub>/CeO<sub>2-X</sub> (50 μg/mL) was injected into the knee joints of OA rats. The articular cartilage (including subchondral bone) of the femoral and tibial sides of the knee joints were harvested at 24, 48, and 72 h after injection, and the knee joints were immersed in saline for 6 h under light avoidance conditions, and then cryosections were performed, stained with DAPI, and sealed, and the images were visualized and recorded under a fuorescence microscope.

#### **Hemolysis assay**

Arterial blood was collected from rats and cell suspension was prepared. Then,  $900 \mu L$  of ultrapure water (positive control) and PBS containing diferent concentrations of PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanozymes were added, and the mixtures were gently shaken and allowed to stand at 37 °C for 2 h. Photographs were taken to compare hemolysis between different groups. The supernatant was transferred to a 96-well plate and the percentage of hemolysis was calculated by recording the absorbance at 540 nm using the enzyme marker.

#### **Statistical analysis**

Data were expressed as mean±standard deviation and found to exhibit a normal/Gaussian distribution under the Shapiro–Wilk test. Analyses were performed using GraphPad Prism software (v. 9.4.1). Unpaired Student's t-test was performed for comparisons between 2 groups, and one-way analysis of variance (ANOVA) was performed for 3 or more groups, followed by Tukey's test. The sample size for each analysis was presented within the figure legends.  $*$  and  $#$  for P < 0.05,  $**$  and  $##$  for P<0.01, \*\*\* and ### for P<0.001, and \*\*\*\* and #### for  $P < 0.0001$ .

#### **Results and discussion**

#### **Preparation and characterization of PtCuO<sub>x</sub>/CeO<sub>2</sub></u> nanozymes**

 $CeO<sub>2</sub>$  nanospheres were synthesized by a hydrothermal method, followed by in situ reduction of Cu and Pt atoms onto  $CeO<sub>2</sub>$  nanospheres using hydrazine hydrate to syn-thesize PtCuO<sub>X</sub>/CeO<sub>2-X</sub> (Fig. [2a](#page-8-0)). Transmission electron microscopy (TEM) revealed that the particle size of the  $CeO<sub>2</sub>$  nanospheres was about 170 nm (Fig. [2b](#page-8-0)), and their lattice spacing was 0.311 nm (Fig. S1), corresponding to the  $CeO<sub>2</sub>$  (111), this crystal surface favors the loading of Cu and Pt nanospheres. As shown in Fig. [2c](#page-8-0),d, Cu and Pt nanospheres were uniformly dispersed on the PtCuO<sub>x</sub>/

 $CeO<sub>2-X</sub>$  nanospheres, and the lattice spacings of 0.224, 0.311, and 0.138 nm corresponded to the PtO<sub>2</sub> (111), CeO<sub>2</sub> (111), and Cu<sub>2</sub>O (310), respectively. Notably, after the Cu and Pt nanospheres deposition, the PtCuO $_{\rm x}/$  $CeO<sub>2-X</sub>$  nanospheres did not change the size and morphology of  $CeO<sub>2</sub>$ . Furthermore, the high-angle annular dark-feld scanning TEM (HAADF-STEM) image (Fig. [2](#page-8-0)e) and energy dispersive X-ray spectroscopy (EDS) spectra (Fig. [2f](#page-8-0)) confrmed the distribution of Ce, O, Cu, and Pt on the PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanospheres. In addition, Fourier transform infrared spectroscopy (FTIR, Fig. [2g](#page-8-0)) showed that  $CeO<sub>2</sub>$  and  $PtCuO<sub>X</sub>/CeO<sub>2-X</sub>$  both exhibited Ce–O bonds at 550  $\text{cm}^{-1}$ , indicating that the structure of  $CeO<sub>2</sub>$  was not disturbed after Pt and Cu deposition. The X-ray diffraction (XRD, Fig. [2h](#page-8-0)) pattern of  $CeO<sub>2</sub>$  nanospheres shows characteristic peaks at 28.5°, 33.1°, 47.5°,

56.3°, 59.1°, 69.4°, 76.7°, and 79.1° (PDF#43–1002). These peaks correspond to the (111), (200), (220), (311), (222), (400), (331), and (420) crystal planes of  $CeO<sub>2</sub>$ , respectively, and while  $PtCuO<sub>x</sub>/CeO<sub>2-x</sub>$  showed diffraction peaks of  $CeO<sub>2</sub>$ , the two peaks at 69.8° (PDF # 01-007-0199) and 40.5° (PDP # 37–1087) correspond to  $Cu<sub>2</sub>O$  $(310)$  and PtO<sub>2</sub> (111), respectively.

The electronic structure of  $PtCuO<sub>X</sub>/CeO<sub>2-X</sub>$  was then analyzed by X-ray photoelectron spectroscopy (XPS). The XPS spectrum of PtCuO<sub>X</sub>/CeO<sub>2-X</sub> (Fig. [2i](#page-8-0)) showed Ce 3d, O 1 s, Cu 2p, and Pt 4f peaks, indicating the successful synthesis of PtCuO<sub>X</sub>/CeO<sub>2-X</sub>. The high-resolution Cu 2p spectra of PtCuO<sub>X</sub>/CeO<sub>2-X</sub> showed four fitted peaks at 932.1 eV (Cu<sup>1+</sup>), 934.6 eV (Cu<sup>2+</sup>), 952.2 eV (Cu<sup>1+</sup>), and 955.0 eV ( $Cu^{2+}$  $Cu^{2+}$  $Cu^{2+}$ ), respectively (Fig. 2j and Table S3). The proportion of Cu<sup>1+</sup> (64.3%, Fig. [2j](#page-8-0)) in PtCuO<sub>X</sub>/



<span id="page-8-0"></span>**Fig. 2** Synthesis and characterization of PtCuO<sub>X</sub>/CeO<sub>2</sub><sub>X</sub>. **a** Schematic diagram of the PtCuO<sub>X</sub>/CeO<sub>2</sub><sub>X</sub> synthesis process. **b** TEM image of CeO<sub>2</sub>. **c** TEM image of PtCuO<sub>X</sub>/CeO<sub>2-X</sub>. **d** HRTEM image of PtCuO<sub>X</sub>/CeO<sub>2-X</sub>, where (I), (II), and (III) represent the lattice spacings of PtO<sub>2</sub>, CeO<sub>2</sub>, and Cu<sub>2</sub>O, respectively. **e** Elemental mapping images and **f** EDS of PtCuO<sub>X</sub>/CeO<sub>2-X</sub>. **g** FTIR spectra, **h** XRD pattern of CeO<sub>2</sub> and PtCuO<sub>X</sub>/CeO<sub>2-X</sub>. **i** XPS and high-resolution XPS spectra of  $j$  Cu 2p, **k** Pt 4f, **l** Ce 3d, and **m** O 1 s of PtCuO<sub>X</sub>/CeO<sub>2-X</sub>

 $CeO<sub>2-X</sub>$  exceeded that of the intermediate  $CuO<sub>X</sub>CeO<sub>2-X</sub>$ (54.3%, Fig. S2a and Table S2). Furthermore, the highresolution Cu 2p spectra of  $PtCuO<sub>X</sub>/CeO<sub>2-X</sub>$  were fitted to obtain  $Cu<sup>1+</sup>$  (932 eV and 952.05 eV), compared with  $CuO_XCeO_{2-X}$ , the peak positions of PtCuO<sub>X</sub>/CeO<sub>2-X</sub> were negatively shifted by 0.8 and 0.6 eV, respectively, indicating electron transfer between atoms. In addition, the high-resolution Pt 4f spectra showed four ftted peaks corresponding to 70.5 eV ( $Pt^0$ ), 72.3 eV ( $Pt^{4+}$ ), 73.9 eV ( $Pt^0$ ), and 76.6 eV ( $Pt^{4+}$ ), respectively (Fig. [2](#page-8-0)k). At the same time, the high-resolution Ce 3d spectrum of PtCuO<sub>X</sub>/CeO<sub>2-X</sub> showed nine fitted peaks at 882.0 eV  $(Ce^{4+})$ , 884.5 eV  $(Ce^{3+})$ , 888.3 eV  $(Ce^{4+})$ , 897.7 eV  $(Ce^{4+})$ , 899.5 eV (Ce<sup>3+</sup>), 900.8 eV (Ce<sup>4+</sup>), 903.0 eV (Ce<sup>3+</sup>), 907.1 eV ( $Ce^{4+}$ ), and 916.8 eV ( $Ce^{4+}$ ) (Fig. [2l](#page-8-0)). Compared to  $CeO<sub>2</sub>$  (Fig. S3a and Table S1), the Ce 3d3/2 and Ce 3d5/2 peaks of the  $PtCuO<sub>X</sub>/CeO<sub>2-X</sub>$  showed negative shifts of 0.9 eV and 0.5 eV, respectively, suggesting electron transfer between atoms. Importantly, since the  $Ce^{3+}$  site of  $CeO<sub>2</sub>$  can be considered as an active center mimicking SOD, the higher  $Ce^{3+}/(Ce^{3+} + Ce^{4+})$  ratio can promote SOD enzyme-like activity. Furthermore, the higher concentration of  $Ce^{3+}$  in  $CeO<sub>2</sub>$  also corresponds to a higher oxygen vacancy content [\[33\]](#page-20-10), [[34](#page-20-11)]. As shown in Fig. [2l](#page-8-0), the Ce<sup>3+</sup>/(Ce<sup>3+</sup> + Ce<sup>4+</sup>) ratio of PtCuO<sub>X</sub>/CeO<sub>2-X</sub> (33.4%) was higher than that of  $CeO<sub>2</sub>$  (26.6%, Fig. S3a). In addition, the split-peak fitting of the  $CeO<sub>2</sub>$  spectra resulted in three ftted peaks corresponding to 528.9 eV  $(O_{\text{Lat}}; O_2^-)$ , 530.7 eV  $(O_{\text{Sur}}; O_2^{2-}, O_2^-)$ , and 532 eV  $(O_{\text{Ads}}; O_2^+)$ -OH,  $CO_3^2$ <sup>--</sup>) (Fig. S3b). The high-resolution O 1 s spectra of PtCuO<sub>X</sub>/CeO<sub>2-X</sub> show four peaks corresponding to 529.0 eV (O<sub>Lat</sub>: O<sub>2</sub><sup>-</sup>), 530.5 eV, and 531.9 eV (O<sub>Sur</sub>: O<sub>2</sub><sup>2-</sup>,  $O_2$ <sup>-</sup>), and 534.2 eV ( $O_{Ads}$ : -OH,  $CO_3$ <sup>2-</sup>), respectively. Compared with the CeO<sub>2</sub> (1.08), PtCuO<sub>X</sub>/CeO<sub>2-X</sub> (1.24) had a higher  $O_{\text{Sur}}/O_{\text{Lat}}$  ratio, which may be due to the presence of more oxygen vacancies after Cu and Pt doping (Fig.  $2m$  $2m$ ) [[35\]](#page-20-12). And the higher concentration of surface oxygen vacancies is benefcial for the adsorption and activation of ROS and RNS, as well as for the enhancement of  $SOD/CAT$ -like activity [\[36\]](#page-20-13). Therefore, the XPS results not only further confrmed the successful synthesis of PtCuO<sub>X</sub>/CeO<sub>2-X</sub>, but also proved its high oxygen vacancy exposure and strong inter-elemental electron transfer interactions, which were benefcial for improving the catalytic performance of  $PtCuO<sub>X</sub>/CeO<sub>2-X</sub>$  nanozymes.

In addition, PtCuO<sub>X</sub>/CeO<sub>2-X</sub> can be uniformly dispersed in PBS, 5%  $H_2O_2$ , fetal bovine serum, and culture medium containing 10% fetal bovine serum within 7 days (Fig. S4). The results showed that the hydration particle size and PDI of  $PtCuO<sub>X</sub>/CeO<sub>2-X</sub>$  remained similar within 7 days, indicating their good dispersion stability in physiological environments.

#### **Photothermal conversion performance and enzyme‑like activity of PtCuOX/CeO2‑X nanozymes**

As shown in Fig. [3a](#page-10-0),b, after 15 min of irradiation with NIR light (808 nm), the PBS buffer and  $CeO<sub>2</sub>$  maintained 27.6 °C and 30.9 °C, respectively. However, the PtCuO $_X$ /  $CeO<sub>2-X</sub>$  increased to 48.5 °C, indicating that the deposition of Cu and Pt on  $CeO<sub>2</sub>$  greatly improves its photothermal conversion performance. The photothermal conversion efficiency of the PtCuO<sub>X</sub>/CeO<sub>2-X</sub> was measured to be 55.41% (Fig. S5c,d), which was higher than that of the  $CeO<sub>2</sub>$  (26.88%, Fig. S5a,b). The photothermal performance of PtCuO<sub>X</sub>/CeO<sub>2-X</sub> increased with higher PtCuO<sub>X</sub>/CeO<sub>2-X</sub> concentration (Fig. S6a) and higher irradiation power (Fig. S6b). In addition, the PtCuO<sub>X</sub>/CeO<sub>2-</sub>  $_{X}$  nanospheres showed no temperature decrease during four repeated "heating/cooling" cycles (Fig. [3c](#page-10-0)), indicating their good photothermal stability.

SOD-catalyzed scavenging of  $O_2$ <sup>-</sup> is the first line of defense for the body's antioxidant response [[37\]](#page-20-9). As shown in Fig.  $3d$  $3d$ , in the electron spin resonance (ESR) map, compared with the blank and  $CeO<sub>2</sub>$ , PtCuO<sub>X</sub>/CeO<sub>2-</sub>  $_X$  reduced the characteristic signals of  $O_2^-$ . Under NIR light irradiation, the characteristic signal was further decreased. The SOD enzyme activity test result (Fig. [3e](#page-10-0)) was consistent with the above conclusion,  $\text{CeO}_2$ , PtCuO<sub>X</sub>/  $CeO<sub>2-X</sub>$ , and PtCuO<sub>X</sub>/CeO<sub>2-X</sub> + NIR had  $·O<sub>2</sub>^-$  scavenging ratios of 22.75%, 47.89%, and 58.84%, respectively, indicating that they had superior  $\cdot \text{O}_2\bar{\phantom{\phi}}$  scavenging ability and SOD-like enzyme activity. In addition, the SOD reaction subsequently generated  $H_2O_2$ , which was then decomposed by PtCuO $_X/CeO_{2-X}$ , mimicking the CAT enzyme activity, to produce  $O_2$  and H<sub>2</sub>O. As shown in Fig. [3f](#page-10-0),g and Fig. S7. PtCuO<sub>X</sub>/CeO<sub>2-X</sub> exhibited superior CATlike enzyme activity by decomposing a larger amount of oxygen produced from the  $H_2O_2$  reaction compared to PBS and  $CeO<sub>2</sub>$ , NIR light irradiation effectively enhanced the catalytic activity of the enzyme. In addition, the SOD/CAT enzyme-like activities of the  $PtCuO<sub>X</sub>/CeO<sub>2-X</sub>$ showed concentration dependence as shown in Fig. S8. Furthermore, by repeatedly adding the same amount of  $H_2O_2$  to the PtCuO<sub>X</sub>/CeO<sub>2-X</sub> solution, it was found that the rate and level of  $O_2$  production remained constant each time, indicating that  $PtCuO<sub>X</sub>/CeO<sub>2-X</sub>$  exhibited stable and sustained CAT-like activity (Fig. [3h](#page-10-0)). Similarly, PtCuO<sub>X</sub>/CeO<sub>2-X</sub> also exhibited superior  $\cdot$ OH scavenging ability compared to  $CeO<sub>2</sub>$ , and the scavenging activity was further enhanced under NIR light irradiation. Compared to  $CeO_2$  (25.82%) and PtCuO<sub>X</sub>/CeO<sub>2-X</sub> (40.09%),  $PtCuO<sub>X</sub>/CeO<sub>2-X</sub> + NIR showed excellent scavensing of$ ·OH (51.13%, Fig. [3](#page-10-0)i, j). When tested with ABTS probes, PtCuO<sub>X</sub>/CeO<sub>2-X</sub> showed a superior ability to scavenge total ROS, which is consistent with the above results



<span id="page-10-0"></span>Fig. 3 Photothermal characterization and free radical scavenging ability of PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanozymes. a Photothermal images and b photothermal curves of PBS, CeO<sub>2</sub>, and PtCuO<sub>X</sub>/CeO<sub>2-X</sub> (50 μg/mL, 808 nm, 1.0 W/cm<sup>2</sup>). **c** Photothermal curve of PtCuO<sub>X</sub>/CeO<sub>2-X</sub> (50 μg/mL, 808 nm, 1.0 W/ cm<sup>2</sup>) to analyze the heating and cooling temperature profiles. **d** The ∙O<sub>2</sub>−scavenging ability measured by ESR. **e** SOD and **f** CAT activity measured by ROS detection kit. **g** Oxygen content from decomposition of H<sub>2</sub>O<sub>2</sub> by PBS, CeO<sub>2</sub>, and PtCuO<sub>X</sub>/CeO<sub>2-X</sub>. **h** Oxygen content in the aqueous solution of PtCuO<sub>x</sub>/CeO<sub>2-X</sub> was measured after repeated addition of H<sub>2</sub>O<sub>2</sub>. **i** ·OH scavenging ability measured by ESR. **j** Scavenging ability of CeO<sub>2</sub>, PtCuO<sub>X</sub>/ CeO<sub>2-X</sub>, and PtCuO<sub>X</sub>/CeO<sub>2-X</sub> + NIR was evaluated for ·OH. **k** for ABTS. I Schematic diagram of the antioxidant process of PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanozymes. Data are expressed as mean  $\pm$  SD (n=3). \* and # for P < 0.05, \*\* and ## for P < 0.01, \*\*\* and ### for P < 0.001, and \*\*\*\* and #### for P < 0.001, and \*\*\*\* and #### for P < 0.0001

(Fig. [3](#page-10-0)k). RNS scavenging also contributed to the protection of chondrocytes from oxidative stress damage and the restoration of mitochondrial function. Fortunately,  $PtCuO<sub>x</sub>/CeO<sub>2-x</sub>$  also showed good RNS scavenging ability. The DPPH scavenging rates of  $PtCuO<sub>X</sub>/CeO<sub>2-X</sub>$  and PtCuO<sub>X</sub>/CeO<sub>2-X</sub> + NIR were 24.91% and 34.35%, respectively, surpassing that of  $CeO<sub>2</sub>$  (15.67%, Fig. S9). Therefore, PtCuO<sub>x</sub>/CeO<sub>2-X</sub> nanozymes have photo-enhanced SOD/CAT enzyme activity as well as an excellent ability to scavenge ROS/RNS (Fig. [3l](#page-10-0)), which is expected to alleviate oxidative stress in the treatment of OA.

#### **DFT studies on the enzyme activity of PtCuO<sub>x</sub>/CeO<sub>2</sub>, nanozymes**

We used density functional theory (DFT) calculations to investigate the origin of the high SOD/CAT-like catalytic efficiency of  $PtCuO<sub>x</sub>/CeO<sub>2-x</sub>$  nanozymes. Based on the characterization results, we constructed a simulated model of PtCuO<sub>X</sub>/CeO<sub>2-X</sub> (Fig. S10). The partial density of states (PDOS) of  $PtCuO<sub>X</sub>/CeO<sub>2-X</sub>$  nanozymes showed a significant overlap between the Cu, Pt, and  $\text{CeO}_2$ , indicating a strong orbital hybridization and interaction among them (Fig.  $4a$  $4a$ ). The differential charge map of PtCuO<sub>x</sub>/CeO<sub>2-X</sub> nanozymes showed the electron transfer between Cu, Pt, and Ce, which facilitated the stabilization of Pt and Cu dispersion on  $CeO<sub>2</sub>$  (Fig. [4b](#page-12-0)). Importantly, the oxygen vacancy formation energy of  $PtCuO<sub>x</sub>/CeO<sub>2-X</sub>$ nanozymes (2.39 eV) was found to be lower than that of  $CeO<sub>2</sub>$  (2.55 eV, Fig. [4c](#page-12-0),d), indicating that the introduction of Cu and Pt on the CeO<sub>2</sub> contributed to the formation of oxygen vacancies, which was consistent with the above conclusion. In addition, the PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanozymes exhibited higher adsorption energies for  $H_2O_2$ ,  $O_2$ ,  $O_3$ and  $H_2O$  compared to  $CeO<sub>2</sub>$  (Fig. S11a and Table S4). Compared to the  $CeO<sub>2</sub>$ , the differential charge distribution map of  $PtCuO_X/CeO_{2-X}$  nanozymes showed electron transfer between the  $PtCuO<sub>x</sub>/CeO<sub>2-x</sub>$  nanozymes, further stabilizing the small molecules on the surface (Fig. [4](#page-12-0)e and Fig. S11b). There was a stronger overlap between Cu d-orbitals, Pt d-orbitals, and O 2p orbitals with P orbitals of small molecules, indicating enhanced adsorption of reaction intermediates by  $PtCuO<sub>x</sub>/CeO<sub>2-x</sub>$ , which was beneficial for PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanozymes to catalyze SOD/CAT reactions of small molecules.

For the SOD-like catalyzed reaction (Fig. [4f](#page-12-0)), the reaction adsorption energies of  $PtCuO<sub>X</sub>/CeO<sub>2-X</sub>$  nanozymes were lower than those of  $CeO<sub>2</sub>$  at each step (Fig. [4g](#page-12-0)), indicating that PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanozymes convert  $\cdot$ O<sub>2</sub><sup>-</sup> to  $H_2O_2$  and  $O_2$  more readily than  $CeO_2$ . Notably, the ratelimiting step of the SOD-catalyzed process was identifed as  $\cdot$ O<sub>2</sub><sup>-</sup> + 2H<sup>+</sup> + Cluster<sup>+</sup> → H<sub>2</sub>O<sub>2</sub> + Cluster<sup>2+</sup>. The energy barrier for this rate-determining step was reduced by PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanozymes (0.22 eV) compared to CeO<sub>2</sub>

(0.76 eV), suggesting that the kinetics of the SOD reaction on PtCuO<sub>x</sub>/CeO<sub>2-X</sub> were significantly enhanced. We used the same analytical method to map the energy distribution of  $H_2O_2$  decomposition on CeO<sub>2</sub> and PtCuO<sub> $x$ </sub>/  $CeO<sub>2-X</sub>$  nanozymes (Fig. [4h](#page-12-0), i). The CAT reaction starts as  $H_2O_2 \rightarrow^* H_2O_2 \rightarrow^* H_2O +^* O$ . The adsorption energy of  $H_2O_2$  on PtCuO<sub>X</sub>/CeO<sub>2-X</sub> (-0.6 eV) is higher than its adsorption on  $CeO<sub>2</sub>$  (-0.07 eV, Fig. S11a), indicating that  $H_2O_2$  is more easily adsorbed on PtCuO<sub>X</sub>/CeO<sub>2-X</sub> than on  $\text{CeO}_2$ , which is more favorable for the subsequent cleavage reaction. In addition, the dissociation of adsorbed  $H_2O_2$  into OH ( $H_2O_2 \rightarrow 2OH$ ) is the rate-limiting step for PtCuO<sub>x</sub>/CeO<sub>2-X</sub> nanozymes to exert CAT enzyme-like effects. Compared with CeO<sub>2</sub> (0.83 eV), PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanozymes (0.54 eV) exhibited a lower energy barrier for the rate-determining step, which signifcantly enhanced the CAT reaction kinetics. Therefore, compared with  $CeO<sub>2</sub>$ , PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanozymes can increase the oxygen vacancies and have stronger electron transfer interaction, thus facilitating the adsorption energy for reaction intermediates and lowering the energy barrier, which improved the SOD/CAT-like reaction kinetics and enzyme catalytic activity.

#### **In vitro study of PtCuOX/CeO2‑X nanozymes for ROS/RNS scavenging and mitochondrial function protection**

Excessive ROS and RNS promote the expression of infammatory factors and also induce chondrocyte apoptosis and extracellular matrix degradation, accelerating the development of OA [\[38\]](#page-20-14). To investigate this, IL-1βinduced chondrocytes were used as an in vitro model [[39\]](#page-20-15). The optimal concentration for cell growth was first determined using a CCK-8 assay (Fig. S12a). Based on the results, it was observed that the cell activity remained more than 90% in the range of 80 μg/mL, and the best cell activity was observed at the concentration of 50 μg/ mL, which was therefore selected as the concentration for subsequent validation. Subsequently, as shown in Fig. S12b, cell viability was severely inhibited in the IL-1βinduced inflammation group, while  $CeO<sub>2</sub>$  and PtCuO<sub>X</sub>/  $CeO<sub>2-X</sub>$  nanozymes were able to rescue damaged chondrocytes, and this efect was further enhanced by NIR light irradiation. Consistent with the results of live-dead staining in Fig. S13a, there were a large number of dead chondrocytes (red signals) in the infammation group, the live/dead ratio of chondrocytes after IL-1β stimulation was 3.71%,  $CeO<sub>2</sub>$ ,  $PtCuO<sub>X</sub>/CeO<sub>2-X</sub>$ , and  $PtCuO<sub>X</sub>/CeO<sub>2</sub>$ .  $x + NIR$  treatments were increased to 8.02%, 12.08%, and 19.92%, respectively (Fig. S13b). The results in Fig. S14 showed the presence of Cy5-labeled PtCuO<sub>X</sub>/CeO<sub>2-</sub>  $_{\text{X}}$  red fluorescence signal in chondrocytes, which gradually increased within 12 h, indicating that the  $PtCuO<sub>x</sub>/$  $CeO<sub>2-X</sub>$  nanozymes were effectively taken up by the cells.



<span id="page-12-0"></span>Fig. 4 DFT study on the SOD and CAT activities of PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanozymes. a PDOS and **b** differential charge density map of PtCuO<sub>X</sub>/CeO<sub>2-X</sub>. **c** Calculation of the oxygen vacancy formation energy of CeO<sub>2</sub> and **d** PtCuO<sub>X</sub>/CeO<sub>2-X</sub>. **e** Differential charge density map and PDOS of different adsorbates (H<sub>2</sub>O<sub>2</sub>, O<sub>2</sub>, O, H<sub>2</sub>O) adsorbed on the surface of PtCuO<sub>X</sub>/CeO<sub>2-X</sub>. **f** Proposed catalytic mechanism and **g** Free energy diagrams for SOD-like activity of CeO<sub>2</sub> and PtCuO<sub>X</sub>/CeO<sub>2-X</sub>. h) Proposed catalytic mechanism and **i** Free energy diagrams for CAT-like activity of CeO<sub>2</sub> and PtCuO<sub>X</sub>/CeO<sub>2-X</sub>

Detection of intracellular ROS and RNS scavenging capacity was performed using specifc fuorescent probes, including ROS,  $\cdot$ O<sub>2</sub><sup>-</sup>,  $\cdot$ OH, NO, and O<sub>2</sub> (Fig. [5](#page-13-0)a,b and Fig. S15). Minimal fuorescence signals were observed in the control group. However, upon IL-1β induction, the fuorescence signals were signifcantly enhanced, indicating

the generation of a substantial amount of ROS and RNS. Compared with a slight decrease in fuorescence intensity of the CeO<sub>2</sub> group, the PtCuO<sub>X</sub>/CeO<sub>2-X</sub> group showed a signifcant decrease in fuorescence intensity, which was better under the NIR irradiation.



<span id="page-13-0"></span>with various ROS assay kits and **b** corresponding quantification to assess the scavenging capacity of ROS, ∙O<sub>2</sub>−, ∙OH, and NO, respectively. **c** Chondrocyte staining with mitochondrial membrane potential probe (JC-1) and **d** corresponding quantifcation to assess the membrane potential. **e** Chondrocyte staining with MitoSOX probe and **f** corresponding quantifcation to assess the level of endogenous ROS. **g** Chondrocyte staining with Fluo-4 AM probe and **h** corresponding quantification to assess the disturbance of Ca<sup>2+</sup> efflux. i) ATP assay kit to assess ATP levels in chondrocytes after diferent treatments. **j** 7-AAD/Annexin V-APC apoptosis kit to assess apoptosis in chondrocytes after diferent treatments. **k** Western blotting and **l** quantitative analysis to assess Bax, Caspase-3, and Bcl-2 protein levels. Concentration: 50 μg/mL; NIR parameters: 808 nm, 1.0 W/cm<sup>2</sup>, 5 min. Data are expressed as mean ± SD (n = 3). \* and # for P < 0.05, \*\* and ## for P < 0.01, \*\*\* and ### for P < 0.001, and \*\*\*\* and #### for P<0.0001

The ROS/RNS are products of mitochondrial energy metabolism, scavenging excessive ROS/RNS can restore mitochondrial dysfunction, thus delaying OA. As shown in Fig.  $5c,d$  $5c,d$ , IL-1β-induced chondrocytes exhibited increased green fuorescence (JC-1 monomers) and decreased red fuorescence (JC-1 aggregates), suggesting that mitochondrial damage led to a decrease in membrane potential. With the treatment of  $CeO<sub>2</sub>$ , PtCuO<sub>x</sub>/  $CeO<sub>2-X</sub>$ , PtCuO<sub>X</sub>/CeO<sub>2-X</sub> + NIR, the red fluorescence gradually increased and the green fuorescence gradually decreased, indicating that  $PtCuO<sub>X</sub>/CeO<sub>2-X</sub>$  can significantly ameliorate the mitochondrial damage, even better under NIR irradiation. The results of the JC-1 flow cytometry were consistent with the above results (Fig. S16). Similarly, the PtCuO<sub>X</sub>/CeO<sub>2-X</sub> + NIR group was more efective in scavenging mitochondrial ROS compared to the other four groups (Fig. [5e](#page-13-0), f). In addition, IL-1β induced an increase in intracellular  $Ca^{2+}$  accumulation compared to the normal group, indicating impaired intracellular  $Ca^{2+}$  homeostasis due to mitochondrial damage. However, the abnormal  $Ca^{2+}$  accumulation was reduced by the CeO<sub>2</sub>, PtCuO<sub>X</sub>/CeO<sub>2-X</sub>, especially PtCuO<sub>X</sub>/CeO<sub>2-X</sub> + NIR, indicating the strong mitochondrial protective efect (Fig. [5](#page-13-0)g,h). Furthermore, the adenosine triphosphate (ATP) content was used to evaluate the intracellular energy metabolism [[40\]](#page-20-16). As shown in Fig. [5i](#page-13-0), and Fig. S17, PtCuO<sub>X</sub>/CeO<sub>2-X</sub> + NIR significantly promoted ATP production in IL-1β-induced cells, which was more significant than  $CeO<sub>2</sub>$  and PtCuO<sub>X</sub>/CeO<sub>2-X</sub>.

 $PtCuO<sub>X</sub>/CeO<sub>2-X</sub>$  nanozymes have excellent SOD/ CAT enzyme activity, and their catalytic activity can be enhanced by photo thermolysis, which can efectively remove ROS/RNS, restore mitochondrial function and protect chondrocytes from apoptosis. As shown in Fig. [5j](#page-13-0), the apoptosis rate of chondrocytes was gradually decreased by the CeO<sub>2</sub> (22.4%), PtCuO<sub>X</sub>/CeO<sub>2-X</sub> (15.2%), and PtCuO<sub>x</sub>/CeO<sub>2-X</sub> + NIR (10.6%) groups compared with the IL-1β group (37.7%). Mechanistically, Bax, Caspase-3, and Bcl-2 [[41–](#page-20-17)[43](#page-20-18)], as key apoptotic factors in their activated state, can provide insights into the intrinsic properties of PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanozymes in inhibiting apoptosis. Fig. S18 shows an increase in the expression of Bax and Caspase-3 and a decrease in Bcl-2 in the IL-1β group. However, compared with the control and  $CeO<sub>2</sub>$  groups, PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanozymes effectively reversed these changes, and the efect was further enhanced by NIR irradiation. The above results were further confrmed by Western blot analysis (Fig. [5k](#page-13-0), l).

#### **PtCuOX/CeO2‑X nanozymes reduce oxidative stress for anti‑infammatory efects**

Infammatory degeneration was a typical feature of OA progression  $[44]$  $[44]$ . To elucidate the anti-inflammatory

capacity of PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanozymes, we performed gene expression analysis of relevant infammatory markers. It is well known that interleukin 6 (IL-6), in addition to matrix metalloproteinase 13 (MMP-13), plays a key role in the induction of matrix-degrading enzymes that contribute to cartilage degeneration and metastasis. In contrast, Col2a1 is a critical component of the extracellular matrix essential for cartilage regeneration [[45](#page-20-20)[–47](#page-20-21)]. Figure [6a](#page-15-0) showed that the IL-1β group had higher fluorescence intensity (IL-6 and MMP-13) and lower expression of Col2a1 compared to the normal group. However, the expression of IL-6 and MMP-13 induced by IL-1β was reversed by CeO<sub>2</sub> and PtCuO<sub>x</sub>/CeO<sub>2-X</sub> treatments. Moreover, under NIR irradiation, the effect of  $PtCuO<sub>X</sub>/$  $CeO<sub>2.X</sub>$  was even more significant (Fig. [6](#page-15-0)b).

In addition, the results of quantitative real-time polymerase chain reaction (qRT-PCR) showed that compared with the normal group, MMP-13, IL-6, tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ), and inducible nitric oxide synthase (iNOS) were significantly upregulated, while  $Col2\alpha1$ and aggregated proteoglycan (ACAN) were signifcantly downregulated in the IL-1β group  $[48-50]$  $[48-50]$  $[48-50]$ . Compared with the IL-1β group, CeO<sub>2</sub>, and PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanozymes decreased the expression of infammatory genes, especially under NIR irradiation. And PtCuO $_{\rm X}$ /  $CeO<sub>2-X</sub> + NIR group also increased the expression of$ ACAN and Col2a1 (Fig. [6c](#page-15-0)). The results of the ELISA test further confrmed the above results (Fig. S19).

Mechanistically, the ROS/Rac-1/NF-κB pathway plays a key role in accelerating the progression of OA during the infammatory response, catabolism, and apoptosis [\[51](#page-20-24)]. In OA, overproduction of ROS is involved in multiple signaling pathways activated by injury or cytokines, including causing an increase in the activation of ras-related C3 botulinum toxin substrate 1 (Rac-1) and activation of the nuclear factor-κB (NF-κB) pathway to amplify the infammatory response [\[52](#page-20-25), [53](#page-20-26)]. Aberrant activation of Rac-1 and NF-κB can exacerbate joint damage by promoting tissue infammation, synthesis of catabolic factors, and apoptosis of articular chondrocytes [[54.](#page-20-27) Further, in the activated state, the IκB protein in the cytoplasm is phosphorylated and degraded upon chemical or mechanical stimulation. Subsequently, NF-κB dimers are released and translocated to the nucleus to induce transcription of target genes. In response to IL-1β, NF-κB is markedly upregulated, promotes nuclear translocation of p65, activates Rac-1, and contributes to the progression of infammation [[55](#page-20-28)]. Western blotting analyses showed that the PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanozymes signifcantly inhibited IL-1β-induced elevation of Rac-1 protein levels and *p*-p65/p65 ratio, and this efect was enhanced under NIR irradiation (Fig. [6d](#page-15-0)-f). Therefore, PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanozymes remodel the IL-1β-induced



<span id="page-15-0"></span>Fig. 6 Anti-inflammatory and protective effects of PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanozymes at the cellular level and their mechanisms. a Fluorescence images and **b** quantification of fluorescence intensity of immunofluorescence staining (MMP-13, IL-6, and Col2a1) of chondrocytes to evaluate relative protein expression levels. **c**) Relative RNA expression levels of infammatory genes (MMP-13, IL-6, TNF-α, iNOS,) and chondrocyte-specifc genes (ACAN and Col2a1) in chondrocytes after diferent treatments evaluated by qRT-PCR. **d** Western blot and **e**–**f** quantifcation analysis to evaluate the protein levels of Rac1, *p*-p65, and p65. **g** Mechanism of action of PtCuO<sub>x</sub>/CeO<sub>2-X</sub> nanozymes on ROS/Rac-1/NF-κB signaling pathway. Concentration: 50 µg/mL; NIR Parameters: Wavelength: 808 nm, Power: 1.0 W/cm<sup>2</sup>, and Duration: 5 min. Data are expressed as mean $\pm$  SD (n = 3). \* and # for P < 0.05, \*\* and ## for P < 0.01, \*\*\* and ### for P < 0.001, and \*\*\*\* and #### for P < 0.0001

microenvironment in chondrocytes by attenuating the ROS/Rac-1/NF-κB signaling pathway, thereby ameliorating OA (Fig.  $6g$ ).

#### **In vivo study of PtCuOX/CeO2‑X nanozymes for OA therapy**

To further evaluate the therapeutic effect of  $PtCuO<sub>x</sub>/$  $CeO<sub>2-X</sub>$  nanozymes on OA in vivo, we established an OA model using anterior cruciate ligament dissection  $(ACLT)$  [\[56](#page-20-29)] (Fig. [7](#page-17-0)a). The in vivo photothermal effect of PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanozymes confirmed their potential for photothermal therapy (Fig. [7b](#page-17-0),c). PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanoparticles had cartilage penetration ability and could efectively penetrate the extracellular matrix into the cartilage layer and even the subchondral bone (Fig. S20). In addition, PtCuO<sub>X</sub>/CeO<sub>2-X</sub> was mainly metabolized through the hepatic and renal pathways after intra-articular injection and was cleared within 1 week (Fig. S21). Interestingly, PtCuO<sub>x</sub>/CeO<sub>2-X</sub> did not induce immune rejection. (Fig. S22 and Fig. S23). As shown in Fig. [7](#page-17-0)d, after 4 and 8 weeks of treatment, the femoral and tibial articular surfaces and cartilage surfaces were smooth in the sham group. However, in the OA group, the articular cartilage layer showed obvious wear, with concave and convex surfaces, as well as obvious bone erosion and fissures, indicating the successful establishment of the OA rat model. After treatment with  $PtCuO<sub>X</sub>/CeO<sub>2-X</sub>$  nanozymes, cartilage damage, and erosion were signifcantly reduced, and the efect was better under NIR irradiation. Based on the Pelletier score [[57\]](#page-20-30), the PtCuO<sub>x</sub>/CeO<sub>2-X</sub> + NIR group showed a signifcant decrease in score compared to the OA group, with a decrease of 60.51% and 60.91% at 4 and 8 weeks, respectively (Fig. [7e](#page-17-0)). Next, hematoxylin and eosin (H&E) staining (Fig. [7f](#page-17-0)) and safranin O staining (Fig. [7](#page-17-0)g) showed signifcant fssures, matrix loss, thin and irregular cartilage layer, and signifcant cartilage layer destruction in the OA group compared with the normal group. Fortunately, PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanozymes can efectively reverse the above pathological changes, especially after supplementation with NIR radiation, and the articular surface can be restored to a near-normal level. Finally, according to the OARSI score [[58\]](#page-20-31) (Fig. [7](#page-17-0)h), after treatment with  $PtCuO<sub>X</sub>/CeO<sub>2-X</sub>$  nanozymes, the score decreased by 46.65% compared with the OA group and signifcantly decreased by 74.15% under NIR irradiation. Therefore, PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanozymes exhibit signifcant cartilage protection with the assistance of NIR irradiation.

Immunohistochemical staining showed that the OA group had the highest number of brown heterostained particles, indicating a signifcant expression of MMP-13, IL-6, Rac-1, and *p*-p65. However, the PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanozymes downregulated the expression of the above proteins beyond the effect of  $CeO<sub>2</sub>$  alone. Moreover, the efect was further enhanced under NIR irradiation. In addition, compared with CeO<sub>2</sub> alone, PtCuO<sub> $\chi$ </sub>/CeO<sub>2-X</sub> nanozymes upregulated the expression level of Col2a1 protein, indicating that it promoted cartilage repair (Fig. [8](#page-18-0)a and Fig. S24). Next, an ELISA assay to assess the level of expression of infammatory factors in the synovial fuid yielded results consistent with those described above (Fig. [8](#page-18-0)b). Meanwhile, the ROS content in articular cartilage of the OA group was 14.52 times higher than that of the sham group. The ROS content of  $CeO<sub>2</sub>$ , PtCuO<sub>X</sub>/CeO<sub>2-X</sub>, and PtCuO<sub>X</sub>/CeO<sub>2-X</sub> + NIR group in articular cartilage gradually decreased. Especially, the PtCuO<sub>x</sub>/CeO<sub>2-X</sub> + NIR group showed a 68% decrease, indicating that it had the best efect in scavenging ROS from articular cartilage (Fig. S25). Under the ROS persisted, PtCuO<sub>X</sub>/CeO<sub>2-X</sub> continued to exert antioxidant efects [\[59](#page-20-32)] (Fig. S26). Next, as shown in Fig. [8c](#page-18-0)-e, the results of gait analysis indicated that the  $PtCuO<sub>x</sub>/CeO<sub>2</sub>$ .  $x + NIR$  group showed the most favorable recovery in walking time and average walking speed compared to the OA group.

Finally, the result of H&E staining (Fig. S27) indicated that the major organs showed no signifcant histopathological necrosis or infammatory lesions, suggesting that there was no internal organ damage during the OA treatment with  $PtCuO<sub>X</sub>/CeO<sub>2-X</sub>$  nanozymes. Similarly, the results of the hemolysis experiment further supported the above findings (Fig. S28). The results of blood biochemical analysis in rats showed no diference in biochemical indicators in the PtCuO<sub>X</sub>/CeO<sub>2-X</sub> + NIR group compared with the sham group (Fig. S29). Therefore, PtCuO<sub>X</sub>/CeO<sub>2-X</sub> nanozymes have good biosafety in vivo and have excellent potential for the treatment of OA.

#### **Conclusion**

In summary, according to the "defect engineering construction strategy", we developed  $PtCuO<sub>x</sub>/$  $CeO<sub>2-X</sub>$  nanozymes as highly efficient SOD/CAT mimics by introducing bimetallic Cu and Pt into  $CeO<sub>2</sub>$ nanospheres to enhance the oxygen vacancies, in an attempt to combine NIR irradiation to regulate microenvironment for OA therapy. Doping Cu and Pt on CeO<sub>2</sub> significantly increased the  $Ce^{3+}/Ce^{4+}$  ratio to enhance the oxygen vacancies, while  $CeO<sub>2</sub>(111)$  promoted the homogeneous dispersion of Cu and Pt. In particular, the DFT results proved that the  $PtCuO<sub>x</sub>/$  $CeO<sub>2-X</sub>$  nanozymes decreased the oxygen vacancy formation energy, promoted electron transfer, exposed the active center, increased the interfacial adsorption energy, and decreased the reaction activation energy, thus improving the SOD/CAT-like activity. Besides, the nanozymes have excellent photothermal conversion efficiency (55.41%). Further, PtCuO<sub>X</sub>/CeO<sub>2-X</sub>



<span id="page-17-0"></span>Photothermal images and **c** photothermal curves of rat knee joints after the injection of PBS, CeO<sub>2</sub>, and PtCuO<sub>X</sub>/CeO<sub>2-X</sub>, respectively. **d** Gross observations and **e** macroscopic scores of knee joints at 4 and 8 weeks. **f** HE stained images, **g** safranin O staining, and **h** OARSI scores of knee joints at 4 and 8 weeks. Concentration: 50 μg/mL and 100 μL per injection, with injections once a week. NIR Parameters: Wavelength: 808 nm, Power: 1.0 W/cm<sup>2</sup>, and Duration: 5 min. Data are expressed as mean ± SD (n = 3). \* and # for P < 0.05, \*\* and ## for P < 0.01, \*\*\* and ### for P < 0.001, and \*\*\*\* and #### for P<0.0001



<span id="page-18-0"></span>Fig. 8 In vivo treatment with PtCuO<sub>x</sub>/CeO<sub>2-X</sub> nanozymes to inhibit inflammatory gene expression and attenuate OA. a IHC staining of the articular cartilage after 4 and 8 weeks of treatment. **b** Levels of infammatory factors (MMP-13, IL-6) and chondrocyte-specifc genes (Col2a1) in synovial fuid were determined using ELISA kits after 8 weeks of treatment. **c** Paw prints of rats walking on the CaitWalk platform. **d** Left hind paw swing time and **e** walking speed were measured using gait analysis after 4 and 8 weeks of treatment. Concentration: 50 μg/mL and 100 μL per injection, with injections once a week. NIR Parameters: Wavelength: 808 nm, Power: 1.0 W/cm<sup>2</sup>, and Duration: 5 min. Data are expressed as mean $\pm$  SD (n = 3).  $^*$ and # for P < 0.05, \*\* and ## for P < 0.01, \*\*\* and ### for P < 0.001, and \*\*\*\* and #### for P < 0.0001

nanozymes efectively scavenged intracellular ROS and RNS, protected mitochondrial function, and inhibited the infammatory factors, thus reducing chondrocyte apoptosis. In vivo, experiments demonstrated the biosafety of PtCuO<sub>X</sub>/CeO<sub>2-X</sub> and its potent effect on OA suppression. In particular, NIR radiation further

enhanced the effects. Mechanistically,  $PtCuO<sub>X</sub>/CeO<sub>2-X</sub>$ nanozymes reduced Rac-1 and *p*-p65 protein expression, and ROS levels to remodel the infammatory microenvironment by inhibiting the ROS/Rac-1/NF-κB signaling pathway. This study is a promising strategy for the treatment of various ROS-mediated infammatory diseases.

#### **Supplementary Information**

The online version contains supplementary material available at [https://doi.](https://doi.org/10.1186/s12951-024-02678-z) [org/10.1186/s12951-024-02678-z.](https://doi.org/10.1186/s12951-024-02678-z)

Supplementary file 1.

#### **Acknowledgements**

First-class discipline innovation-driven talent program of Guangxi Medical University

#### **Author contributions**

J.X.Y, S.H.X, and J.J.D contributed equally to this work. L.Z, Q.J.W, and J.P.Z conceived and designed this project. J.X.Y, S.H.X, J.J.D, Y.Q.L, H.H, J.W.W and G.H.L performed the experiments. J.X.Y, S.H.X, L.Z, Q.J.W, C.L, and J.P.Z analyzed and tackled the data. J.H.X, Y.Q.L, and J.P.Z re-arranged the Figures and wrote the manuscript. L.Z and J.P.Z revised the manuscript. L.Z, Q.J.W, and J.P.Z supervised and supported the project. All authors reviewed the manuscript.

#### **Funding**

This study was supported by the Guangxi Natural Science Foundation (2023GXNSFBA026020), the Guangxi Scientifc Research and Technological Development Foundation (Grant No. GuikeAB23026049), National Natural Science Foundation of China (82160429, 52301303, 82360426), the Guangxi Key R&D Program, China (GuiKe AB22035014), Special Fund of Characteristic Innovation Team of the First Afliated Hospital of Guangxi Medical University (YYZS2022003).

#### **Data availability**

The data that support the fndings of this study are available from the corresponding author upon reasonable request.

#### **Declarations**

#### **Ethics approval and consent to participate**

All animal experiments met animal ethics requirements and were approved by the Ethics Committee of Guangxi Medical University. (No: 202209010).

#### **Consent for publication**

There is no confict of interest in submitting this manuscript, and the manuscript is approved for publication by all authors.

#### **Competing interests**

The authors declare that they have no known competing fnancial interests or personal relationships that could have appeared to infuence the work reported in this paper.

#### **Author details**

<sup>1</sup> Guangxi Engineering Center in Biomedical Material for Tissue and Organ Regeneration, Collaborative Innovation Centre of Regenerative Medicine and Medical BioResource Development and Application Co-Constructed By the Province and Ministry, Guangxi Key Laboratory of Regenerative Medicine, The First Afliated Hospital of Guangxi Medical University, Guangxi Medical University, No. 6 Shuangyong Road, Nanning 530021, Guangxi, People's Republic of China. <sup>2</sup> Life Sciences Institute, Guangxi Medical University, No. 22 Shuangyong Road, Nanning, Guangxi 530021, People's Republic of China. <sup>3</sup> Department of Orthopaedics Trauma and Hand Surgery, The First Afliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Nanning, Guangxi 530021, People's Republic of China. <sup>4</sup>School of Materials

and Environment, Guangxi Minzu University, Nanning, Guangxi 53000, People's Republic of China. <sup>5</sup> Department of Orthopedics, The Second Affiliated Hospital of Guangxi Medical University, No. 166 East University Road, Nanning, Guangxi 530005, People's Republic of China.

Received: 4 April 2024 Accepted: 30 June 2024 Published online: 18 August 2024

#### **References**

- <span id="page-19-5"></span>1. Leifer VP, Katz JN, Losina E. The burden of OA-health services and economics. Osteoarthritis Cartilage. 2022;30:10–6.
- <span id="page-19-6"></span>2. Bernabei I, So A, Busso N, Nasi S. Cartilage calcifcation in osteoarthritis: mechanisms and clinical relevance. Nat Rev Rheumatol. 2022;19:10–27.
- <span id="page-19-7"></span>3. Katz JN, Arant KR, Loeser RF. Diagnosis and treatment of hip and knee osteoarthritis. JAMA. 2021;325:568.
- <span id="page-19-8"></span>4. Arra M, Swarnkar G, Ke K, Otero JE, Ying J, Duan X, Maruyama T, Rai MF, O'Keefe RJ, Mbalaviele G, et al. LDHA-mediated ROS generation in chondrocytes is a potential therapeutic target for osteoarthritis. Nat Commun. 2020. [https://doi.org/10.1038/s41467-020-17242-0.](https://doi.org/10.1038/s41467-020-17242-0)
- 5. Blanco FJ, Valdes AM, Rego-Pérez I. Mitochondrial DNA variation and the pathogenesis of osteoarthritis phenotypes. Nat Rev Rheumatol. 2018;14:327–40.
- <span id="page-19-9"></span>6. Shi S, Tian T, Li Y, Xiao D, Zhang T, Gong P, Lin Y. Tetrahedral framework nucleic acid inhibits chondrocyte apoptosis and oxidative stress through activation of autophagy. ACS Appl Mater Interfaces. 2020;12:56782–91.
- <span id="page-19-10"></span>7. Yang B, Chen Y, Shi J. Reactive oxygen species (ROS)-based nanomedicine. Chem Rev. 2019;119:4881–985.
- <span id="page-19-11"></span>8. Kwesiga MP, Gillette AA, Razaviamri F, Plank ME, Canull AL, Alesch Z, He W, Lee BP, Guillory RJ. Biodegradable magnesium materials regulate ROS-RNS balance in pro-infammatory macrophage environment. Bioactive Mater. 2023;23:261–73.
- <span id="page-19-12"></span>9. Winand L, Sester A, Nett M. Bioengineering of anti-inflammatory natural products. Chem Med Chem. 2020;16:767–76.
- <span id="page-19-13"></span>10. Gu L, Shan T, Ma Y-X, Tay FR, Niu L. Novel biomedical applications of crosslinked collagen. Trends Biotechnol. 2019;37:464–91.
- <span id="page-19-14"></span>11. Arnold J, Chapman J, Arnold M, Dinu CZ. Hyaluronic acid allows enzyme immobilization for applications in biomedicine. Biosensors. 2022;12:28.
- <span id="page-19-15"></span>12. Wu J, Li S, Wei H. Multifunctional nanozymes: enzyme-like catalytic activity combined with magnetism and surface plasmon resonance. Nanoscale Horizons. 2018;3:367–82.
- <span id="page-19-16"></span>13. Wang H, Wan K, Shi X. Recent advances in nanozyme research. Adv Mater. 2018;31:e1805368.
- <span id="page-19-17"></span>14. Huang Y, Ren J, Qu X. Nanozymes: classifcation, catalytic mechanisms, activity regulation, and applications. Chem Rev. 2019;119:4357–412.
- <span id="page-19-18"></span>15. Saif MA, Seal S, Godugu C. Nanoceria, the versatile nanoparticles: promising biomedical applications. J Control Release. 2021;338:164–89.
- <span id="page-19-19"></span>16. Gao Y, Zou J, Chen B, Cao Y, Hu D, Zhang Y, Zhao X, Wen J, Liu K, Wang K. Hyaluronic acid/serotonin-decorated cerium dioxide nanomedicine for targeted treatment of ulcerative colitis. Biomater Sci. 2023;11:618–29.
- <span id="page-19-0"></span>17. Lin Y-W, Fang C-H, Meng F-Q, Ke C-J, Lin F-H. Hyaluronic acid loaded with cerium oxide nanoparticles as antioxidant in hydrogen peroxide induced chondrocytes injury: an in vitro osteoarthritis model. Molecules. 2020;25:4407.
- <span id="page-19-1"></span>18. Zhang S, Ruan H, Xin Q, Mu X, Wang H, Zhang X-D. Modulation of the biocatalytic activity and selectivity of CeO2 nanozymes via atomic doping engineering. Nanoscale. 2023;15:4408–19.
- 19. Yang X, Pan H, Wang P, Zhao F-J. Particle-specifc toxicity and bioavailability of cerium oxide (CeO2) nanoparticles to Arabidopsis thaliana. J Hazard Mater. 2017;322:292–300.
- <span id="page-19-2"></span>20. Zhang J, Qin X, Chu X, Chen M, Chen X, Chen J, He H, Zhang C. Tuning metal-support interaction of Pt-CeO2 catalysts for enhanced oxidation reactivity. Environ Sci Technol. 2021;55:16687–98.
- <span id="page-19-3"></span>21. Guo C, Wei S, Zhou S, Zhang T, Wang Z, Ng S-P, Lu X, Wu C-ML, Guo W. Initial reduction of CO2 on Pd-, Ru-, and Cu-doped CeO2(111) surfaces: efects of surface modifcation on catalytic activity and selectivity. ACS Appl Mater Interfaces. 2017;9:26107–17.
- <span id="page-19-4"></span>22. Zhang W, Pu M, Lei M. Theoretical studies on the stability and reactivity of the metal-doped CeO2(100) surface: toward H2 dissociation and oxygen vacancy formation. Langmuir. 2020;36:5891–901.
- <span id="page-20-0"></span>23. Zhang Z, Wang ZL, An K, Wang J, Zhang S, Song P, Bando Y, Yamauchi Y, Liu Y. Ti3+ tuning the ratio of Cu+/Cu0 in the ultrafne Cu nanoparticles for boosting the hydrogenation reaction. Small. 2021. [https://doi.org/10.](https://doi.org/10.1002/smll.202008052) [1002/smll.202008052](https://doi.org/10.1002/smll.202008052).
- <span id="page-20-1"></span>24. Liu X, Jia S, Yang M, Tang Y, Wen Y, Chu S, Wang J, Shan B, Chen R. Activation of subnanometric Pt on Cu-modifed CeO2 via redox-coupled atomic layer deposition for CO oxidation. Nat Commun. 2020. [https://doi.](https://doi.org/10.1038/s41467-020-18076-6) [org/10.1038/s41467-020-18076-6](https://doi.org/10.1038/s41467-020-18076-6).
- <span id="page-20-2"></span>25. Zou L, Pan J, Xu F, Chen J. Cu assisted loading of Pt on CeO2 as a carbonfree catalyst for methanol and oxygen reduction reaction. RSC Adv. 2021;11:36726–33.
- <span id="page-20-3"></span>26. Zhu Y, Zhao R, Feng L, Wang C, Dong S, Zyuzin MV, Timin A, Hu N, Liu B, Yang P. Dual nanozyme-driven PtSn bimetallic nanoclusters for metal-enhanced tumor photothermal and catalytic therapy. ACS Nano. 2023;17:6833–48.
- <span id="page-20-4"></span>27. Yuan M, Kermanian M, Agarwal T, Yang Z, Yousefasl S, Cheng Z, Pa M, Lin J, Maleki A. Defect engineering in biomedical sciences. Adv Mater. 2023;35:e2304176.
- <span id="page-20-5"></span>28. Jiang C, Wei X, Bao S, Tu H, Wang W. Cu@Au(Ag)/Pt nanocomposite as peroxidase mimic and application of Cu@Au/Pt in colorimetric detection of glucose and l-cysteine. RSC Adv. 2019;9:41561–8.
- 29. Xiong P, Niu H, Zhu Z, Zhao L, Zuo J, Gong S, Niu X, Chen JS, Wu R, Xia BY. Engineering a high-loading Sub-4 nm intermetallic platinum-cobalt alloy on atomically dispersed cobalt-nitrogen-carbon for efficient oxygen reduction in fuel cells. Nano Lett. 2024;24:3961–70.
- <span id="page-20-6"></span>30. Zhong J-P, Hou C, Li L, Waqas M, Fan Y-J, Shen X-C, Chen W, Wan L-Y, Liao H-G, Sun S-G. A novel strategy for synthesizing Fe, N, and S tri doped graphene-supported Pt nano dendrites toward highly efficient methanol oxidation. J Catal. 2020;381:275–84.
- <span id="page-20-7"></span>31. Kresse G, Furthmüller J. Efficient iterative schemes for ab initio totalenergy calculations using a plane-wave basis set. Phys Rev B Condens Matter. 1996;54:11169–86.
- <span id="page-20-8"></span>32. Perdew JP, Burke K, Ernzerhof M. Generalized Gradient Approximation Made Simple. Phys Rev Lett. 1996;77:3865–8.
- <span id="page-20-10"></span>33. Sun Y, Liu X, Wang L, Xu L, Liu K, Xu L, Shi F, Zhang Y, Gu N, Xiong F. Highperformance SOD mimetic enzyme Au@Ce for arresting cell cycle and proliferation of acute myeloid leukemia. Bioactive Mater. 2022;10:117–30.
- <span id="page-20-11"></span>34. Yang L, Cai Z, Hao L, Xing Z, Dai Y, Xu X, Pan S, Duan Y, Zou J. Nano Ce2O2S with highly enriched oxygen-defcient Ce3+ sites supported by N and S dual-doped carbon as an active oxygen-supply catalyst for the oxygen reduction reaction. ACS Appl Mater Interfaces. 2017;9:22518–29.
- <span id="page-20-12"></span>35. Sun X, Yang S, Liu X, Qiao Y, Liu Z, Li X, Pan J, Liu H, Wang L. The enhancement of benzene total oxidation over RuxCeO2 catalysts at low temperature: the signifcance of Ru incorporation. Sci Total Environ. 2023;902:165574.
- <span id="page-20-13"></span>36. Wang Z, Shen X, Gao X, Zhao Y. Simultaneous enzyme mimicking and chemical reduction mechanisms for nanoceria as a bio-antioxidant: a catalytic model bridging computations and experiments for nanozymes. Nanoscale. 2019;11:13289–99.
- <span id="page-20-9"></span>37. Xu C, Zhang W, Wang R, Tan S, Holub JM, Tang B. Versatile gold-coupled Te-carbon dots for quantitative monitoring and efficient scavenging of superoxide anions. Anal Chem. 2021;93:9111–8.
- <span id="page-20-14"></span>38. Yu P, Li Y, Sun H, Zhang H, Kang H, Wang P, Xin Q, Ding C, Xie J, Li J. Mimicking antioxidases and hyaluronan synthase: a zwitterionic nanozyme for photothermal therapy of osteoarthritis. Adv Mater. 2023. [https://doi.](https://doi.org/10.1002/adma.202303299) [org/10.1002/adma.202303299.](https://doi.org/10.1002/adma.202303299)
- <span id="page-20-15"></span>39. Largo R, Alvarez-Soria MA, Dıez-Ortego I, Calvo E, Sánchez-Pernaute O, Egido J, Herrero-Beaumont G. Glucosamine inhibits IL-1β-induced NFκB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartil. 2003;11:290–8.
- <span id="page-20-16"></span>40. Paggio A, Checchetto V, Campo A, Menabò R, Di Marco G, Di Lisa F, Szabo I, Rizzuto R, De Stefani D. Identifcation of an ATP-sensitive potassium channel in mitochondria. Nature. 2019;572:609–13.
- <span id="page-20-17"></span>41. King LE, Rodriguez-Enriquez R, Pedley R, Mellor CEL, Wang P, Zindy E, White MRH, Brennan K, Gilmore AP. Apoptotic priming is defned by the dynamic exchange of Bcl-2 proteins between mitochondria and cytosol. Cell Death Difer. 2022;29:2262–74.
- 42. Huang Q, Li F, Liu X, Li W, Shi W, Liu F-F, O'Sullivan B, He Z, Peng Y, Tan A-C, et al. Caspase 3–mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med. 2011;17:860–6.
- <span id="page-20-18"></span>43. Bernardini JP, Brouwer JM, Tan IKL, Sandow JJ, Huang S, Stafford CA, Bankovacki A, Rifkin CD, Wardak AZ, Czabotar PE, et al. Parkin inhibits BAK and BAX apoptotic function by distinct mechanisms during mitophagy. EMBO J. 2018. [https://doi.org/10.15252/embj.201899916.](https://doi.org/10.15252/embj.201899916)
- <span id="page-20-19"></span>44. Zheng L, Zhang Z, Sheng P, Mobasheri A. The role of metabolism in chondrocyte dysfunction and the progression of osteoarthritis. Ageing Res Rev. 2021;66:101249.
- <span id="page-20-20"></span>45. He R, Wang Z, Cui M, Liu S, Wu W, Chen M, Wu Y, Qu Y, Lin H, Chen S, et al. HIF1A Alleviates compression-induced apoptosis of nucleus pulposus derived stem cells via upregulating autophagy. Autophagy. 2021;17:3338–60.
- 46. Lan Q, Lu R, Chen H, Pang Y, Xiong F, Shen C, Qin Z, Zheng L, Xu G, Zhao J. MMP-13 enzyme and pH-responsive theranostic nano platform for osteoarthritis. J Nanobiotechnol. 2020. [https://doi.org/10.1186/](https://doi.org/10.1186/s12951-020-00666-7) [s12951-020-00666-7](https://doi.org/10.1186/s12951-020-00666-7).
- <span id="page-20-21"></span>47. Del Giudice M, Gangestad SW. Rethinking IL-6 and CRP: why they are more than infammatory biomarkers, and why it matters. Brain Behav Immun. 2018;70:61–75.
- <span id="page-20-22"></span>48. Giuliani C. The favonoid quercetin induces AP-1 activation in FRTL-5 thyroid cells. Antioxidants. 2019. [https://doi.org/10.3390/antiox8050112.](https://doi.org/10.3390/antiox8050112)
- 49. Qian H, Neplioueva V, Shetty GA, Channon KM, George SE. Nitric Oxide Synthase Gene Therapy Rapidly Reduces Adhesion Molecule Expression and Infammatory Cell Infltration in Carotid Arteries of Cholesterol-Fed Rabbits. Circulation. 1999;99:2979–82.
- <span id="page-20-23"></span>50. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier J-P, Fahmi H. Role of proinfammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2010;7:33–42.
- <span id="page-20-24"></span>51. Hou W, Ye C, Chen M, Gao W, Xie X, Wu J, Zhang K, Zhang W, Zheng Y, Cai X. Excavating bioactivities of nanozyme to remodel microenvironment for protecting chondrocytes and delaying osteoarthritis. Bioactive Materials. 2021;6:2439–51.
- <span id="page-20-25"></span>52. Zhu S, Dai J, Liu H, Cong X, Chen Y, Wu Y, Hu H, Heng BC, Ouyang HW, Zhou Y. Down-regulation of Rac GTPase-activating protein OCRL1 causes aberrant activation of Rac1 in osteoarthritis development. Arthritis Rheumatol. 2015;67:2154–63.
- <span id="page-20-26"></span>53. Yao Q, Wu X, Tao C, Gong W, Chen M, Qu M, Zhong Y, He T, Chen S, Xiao G. Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Signal Transduction Targeted Ther. 2023. [https://doi.org/10.1038/](https://doi.org/10.1038/s41392-023-01330-w) [s41392-023-01330-w.](https://doi.org/10.1038/s41392-023-01330-w)
- <span id="page-20-27"></span>54. Myant Kevin B, Cammareri P, McGhee Ewan J, Ridgway Rachel A, Huels David J, Cordero Julia B, Schwitalla S, Kalna G, Ogg E-L, Athineos D, et al. ROS production and NF-κB activation triggered by RAC1 facilitate WNTdriven intestinal stem cell proliferation and colorectal cancer initiation. Cell Stem Cell. 2013;12:761–73.
- <span id="page-20-28"></span>55. Turpaev KT. Transcription Factor KLF2 and Its role in the regulation of infammatory processes. Biochemistry. 2020;85:54–67.
- <span id="page-20-29"></span>56. Glasson SS, Blanchet TJ, Morris EA. The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. Osteoarthritis Cartilage. 2007;15:1061–9.
- <span id="page-20-30"></span>57. Pelletier JP, Fernandes JC, Brunet J, Moldovan F, Schrier D, Flory C, Martel-Pelletier J. In vivo selective inhibition of mitogen-activated protein kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. Arthritis Rheum. 2003;48:1582–93.
- <span id="page-20-31"></span>58. Pritzker KPH, Gay S, Jimenez SA, Ostergaard K, Pelletier JP, Revell PA, Salter D, van den Berg WB. Osteoarthritis cartilage histopathology: grading and staging. Osteoarthritis Cartilage. 2006;14:13–29.
- <span id="page-20-32"></span>59. Chen Q, Chen J, Yang Z, Xu J, Xu L, Liang C, Han X, Liu Z. Nanoparticleenhanced radiotherapy to trigger robust cancer immunotherapy. Adv Mater. 2019;31:e1802228.

#### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.